 Angela Rachubinski
Concepts (102)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Down Syndrome | 12 | 2023 | 338 | 2.160 |
Why?
| | Neural Stem Cells | 2 | 2012 | 115 | 0.740 |
Why?
| | Autism Spectrum Disorder | 1 | 2016 | 323 | 0.400 |
Why?
| | tau Proteins | 1 | 2012 | 68 | 0.390 |
Why?
| | Stem Cell Transplantation | 1 | 2012 | 149 | 0.370 |
Why?
| | Cognition Disorders | 1 | 2012 | 476 | 0.300 |
Why?
| | Cognition | 1 | 2012 | 983 | 0.240 |
Why?
| | Receptors, Interferon | 2 | 2023 | 47 | 0.220 |
Why?
| | Aging | 1 | 2012 | 1621 | 0.200 |
Why?
| | Trisomy | 2 | 2019 | 68 | 0.200 |
Why?
| | Janus Kinase Inhibitors | 1 | 2021 | 10 | 0.190 |
Why?
| | Interferon-alpha | 2 | 2019 | 187 | 0.190 |
Why?
| | Arthritis, Psoriatic | 1 | 2021 | 16 | 0.190 |
Why?
| | Brain | 1 | 2012 | 2372 | 0.180 |
Why?
| | Piperidines | 1 | 2021 | 162 | 0.170 |
Why?
| | Animals, Newborn | 2 | 2012 | 777 | 0.170 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2019 | 31 | 0.170 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2023 | 447 | 0.160 |
Why?
| | Kynurenine | 1 | 2019 | 80 | 0.160 |
Why?
| | Behavior, Animal | 2 | 2012 | 462 | 0.160 |
Why?
| | Pyrimidines | 1 | 2021 | 378 | 0.160 |
Why?
| | Autoimmunity | 2 | 2023 | 818 | 0.150 |
Why?
| | T-Lymphocyte Subsets | 1 | 2019 | 384 | 0.140 |
Why?
| | Heart Defects, Congenital | 1 | 2023 | 665 | 0.140 |
Why?
| | Disease Models, Animal | 3 | 2023 | 3549 | 0.130 |
Why?
| | Cell Differentiation | 3 | 2023 | 1699 | 0.120 |
Why?
| | Proteome | 1 | 2017 | 339 | 0.110 |
Why?
| | Mice | 5 | 2023 | 14936 | 0.110 |
Why?
| | Drinking Behavior | 1 | 2012 | 10 | 0.100 |
Why?
| | Interferons | 2 | 2023 | 151 | 0.100 |
Why?
| | Dentate Gyrus | 1 | 2012 | 30 | 0.100 |
Why?
| | Cell Size | 1 | 2012 | 81 | 0.100 |
Why?
| | Maze Learning | 1 | 2012 | 87 | 0.100 |
Why?
| | Neuroimmunomodulation | 1 | 2012 | 70 | 0.100 |
Why?
| | Avoidance Learning | 1 | 2012 | 63 | 0.100 |
Why?
| | 1-Methyl-4-phenylpyridinium | 1 | 2011 | 5 | 0.100 |
Why?
| | Genetic Variation | 1 | 2016 | 876 | 0.100 |
Why?
| | Cell Count | 1 | 2012 | 305 | 0.100 |
Why?
| | NADPH Oxidases | 1 | 2011 | 120 | 0.090 |
Why?
| | Dopaminergic Neurons | 1 | 2011 | 43 | 0.090 |
Why?
| | Green Fluorescent Proteins | 1 | 2012 | 373 | 0.090 |
Why?
| | Animals | 6 | 2023 | 31839 | 0.090 |
Why?
| | Analysis of Variance | 1 | 2012 | 1227 | 0.080 |
Why?
| | Neoplasms | 1 | 2023 | 2106 | 0.080 |
Why?
| | Reactive Oxygen Species | 1 | 2011 | 536 | 0.080 |
Why?
| | Cell Survival | 1 | 2012 | 1022 | 0.080 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1635 | 0.080 |
Why?
| | Hippocampus | 1 | 2012 | 696 | 0.070 |
Why?
| | Inflammation | 1 | 2017 | 2485 | 0.070 |
Why?
| | Mice, Transgenic | 1 | 2012 | 1953 | 0.070 |
Why?
| | Humans | 10 | 2023 | 114937 | 0.060 |
Why?
| | Cells, Cultured | 1 | 2012 | 3897 | 0.060 |
Why?
| | Growth Disorders | 1 | 2022 | 78 | 0.050 |
Why?
| | Gene Silencing | 1 | 2023 | 172 | 0.050 |
Why?
| | Cytokines | 2 | 2019 | 1843 | 0.050 |
Why?
| | Transcriptional Activation | 1 | 2023 | 337 | 0.050 |
Why?
| | Clonal Evolution | 1 | 2021 | 27 | 0.050 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2022 | 286 | 0.050 |
Why?
| | Cell Line | 2 | 2019 | 2640 | 0.040 |
Why?
| | Hematopoiesis | 1 | 2021 | 172 | 0.040 |
Why?
| | Quinolinic Acid | 1 | 2019 | 7 | 0.040 |
Why?
| | Biosynthetic Pathways | 1 | 2019 | 19 | 0.040 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2019 | 44 | 0.040 |
Why?
| | Cellular Senescence | 1 | 2019 | 153 | 0.040 |
Why?
| | Adult | 4 | 2021 | 30608 | 0.040 |
Why?
| | Cell Lineage | 1 | 2019 | 310 | 0.040 |
Why?
| | Receptors, Growth Factor | 1 | 2017 | 49 | 0.040 |
Why?
| | Proteomics | 1 | 2023 | 844 | 0.040 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2019 | 343 | 0.030 |
Why?
| | Mice, Inbred C57BL | 2 | 2019 | 4719 | 0.030 |
Why?
| | Interferon-gamma | 1 | 2019 | 723 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2019 | 1087 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2019 | 1045 | 0.030 |
Why?
| | Phenotype | 1 | 2023 | 2817 | 0.030 |
Why?
| | Female | 5 | 2021 | 59581 | 0.030 |
Why?
| | Transcription Factors | 1 | 2023 | 1530 | 0.030 |
Why?
| | Metabolomics | 1 | 2019 | 527 | 0.030 |
Why?
| | Complement System Proteins | 1 | 2017 | 285 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2019 | 692 | 0.030 |
Why?
| | Gene Expression | 1 | 2019 | 1422 | 0.030 |
Why?
| | Young Adult | 2 | 2019 | 10478 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1523 | 0.030 |
Why?
| | Biomarkers | 1 | 2022 | 3418 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2019 | 3008 | 0.030 |
Why?
| | Losartan | 1 | 2011 | 9 | 0.020 |
Why?
| | Chronic Disease | 1 | 2017 | 1593 | 0.020 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2011 | 29 | 0.020 |
Why?
| | Herbicides | 1 | 2011 | 24 | 0.020 |
Why?
| | Electron Transport Complex I | 1 | 2011 | 33 | 0.020 |
Why?
| | Substantia Nigra | 1 | 2011 | 37 | 0.020 |
Why?
| | Oxidants | 1 | 2011 | 112 | 0.020 |
Why?
| | Protein Subunits | 1 | 2011 | 201 | 0.020 |
Why?
| | Signal Transduction | 1 | 2023 | 4525 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2011 | 287 | 0.020 |
Why?
| | Male | 3 | 2019 | 55663 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2011 | 543 | 0.020 |
Why?
| | Infant | 1 | 2017 | 7937 | 0.010 |
Why?
| | Child, Preschool | 1 | 2017 | 9086 | 0.010 |
Why?
| | Rats | 1 | 2011 | 4963 | 0.010 |
Why?
| | Middle Aged | 1 | 2019 | 26806 | 0.010 |
Why?
| | Adolescent | 1 | 2017 | 17829 | 0.010 |
Why?
| | Child | 1 | 2017 | 18366 | 0.010 |
Why?
|
|
Rachubinski's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|